Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics (NASDAQ: LYRA) reported Q2 2024 financial results and provided a corporate update. Key points include:
1. Primary focus on ENLIGHTEN 1 Phase 3 extension study results expected in Q4 2024 and ENLIGHTEN 2 pivotal Phase 3 trial results in 1H 2025.
2. Further analysis of ENLIGHTEN 1 data showed LYR-210 improved symptomatic endpoints in CRS patients with nasal polyps.
3. Q2 2024 financial highlights: $67.5 million in cash and equivalents, $13.3 million in R&D expenses, and $5.1 million in G&A expenses.
4. Net loss for Q2 2024 was $48.1 million, compared to $15.6 million in Q2 2023.
5. Cost-cutting measures implemented, including a 75% workforce reduction and pausing LYR-220 development.
Lyra Therapeutics (NASDAQ: LYRA) ha comunicato i risultati finanziari per il secondo trimestre del 2024 e fornito un aggiornamento aziendale. I punti chiave includono:
1. Principalmente focalizzati sui risultati dello studio di estensione ENLIGHTEN 1 Fase 3 attesi nel quarto trimestre del 2024 e sui risultati del trial decisivo ENLIGHTEN 2 Fase 3 previsti nel primo semestre del 2025.
2. Ulteriori analisi dei dati di ENLIGHTEN 1 hanno mostrato che LYR-210 ha migliorato i parametri sintomatici in pazienti con CRS e polipi nasali.
3. Risultati finanziari per il secondo trimestre del 2024: 67,5 milioni di dollari in liquidità e equivalenti, 13,3 milioni di dollari in spese di R&S, e 5,1 milioni di dollari in spese generali e amministrative.
4. La perdita netta per il secondo trimestre del 2024 è stata di 48,1 milioni di dollari, rispetto ai 15,6 milioni di dollari nel secondo trimestre del 2023.
5. Sono state attuate misure di riduzione dei costi, inclusa una riduzione del personale del 75% e la sospensione dello sviluppo di LYR-220.
Lyra Therapeutics (NASDAQ: LYRA) informó sobre los resultados financieros del segundo trimestre de 2024 y proporcionó una actualización corporativa. Los puntos clave incluyen:
1. Enfoque principal en los resultados del estudio de extensión ENLIGHTEN 1 Fase 3 esperados para el cuarto trimestre de 2024 y los resultados del ensayo pivotal ENLIGHTEN 2 Fase 3 para la primera mitad de 2025.
2. Un análisis adicional de los datos de ENLIGHTEN 1 mostró que LYR-210 mejoró los puntos finales sintomáticos en pacientes con CRS y pólipos nasales.
3. Destacados financieros del segundo trimestre de 2024: 67,5 millones de dólares en efectivo y equivalentes, 13,3 millones de dólares en gastos de I+D y 5,1 millones de dólares en gastos generales y administrativos.
4. La pérdida neta para el segundo trimestre de 2024 fue de 48,1 millones de dólares, en comparación con los 15,6 millones de dólares en el segundo trimestre de 2023.
5. Se implementaron medidas de reducción de costos, incluyendo una reducción del 75% de la fuerza laboral y la pausa en el desarrollo de LYR-220.
Lyra Therapeutics (NASDAQ: LYRA)는 2024년 2분기 재무 결과를 발표하고 기업 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
1. 2024년 4분기에 예상되는 ENLIGHTEN 1 3상 연장 연구 결과와 2025년 1분기에 있을 ENLIGHTEN 2 주요 3상 시험 결과에 주력하고 있습니다.
2. ENLIGHTEN 1 데이터에 대한 추가 분석 결과 LYR-210이 CRS 환자에서 증상 종결점을 개선했다고 밝혔습니다.
3. 2024년 2분기 재무 하이라이트: 6,750만 달러의 현금 및 현금성 자산, 1,330만 달러의 연구개발비, 510만 달러의 일반관리비가 수록되었습니다.
4. 2024년 2분기 순손실은 4,810만 달러였으며, 이는 2023년 2분기의 1,560만 달러에 비해 증가한 수치입니다.
5. 75%의 인력 감소와 LYR-220 개발 중단을 포함한 비용 절감 조치가 시행되었습니다.
Lyra Therapeutics (NASDAQ: LYRA) a rapporté les résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour de l'entreprise. Les points clés incluent :
1. Concentration principale sur les résultats de l'étude d'extension ENLIGHTEN 1 Phase 3 attendus au quatrième trimestre 2024 et sur les résultats de l'essai pivot ENLIGHTEN 2 Phase 3 prévus au premier semestre 2025.
2. Une analyse plus approfondie des données d'ENLIGHTEN 1 a montré que LYR-210 a amélioré les points finaux symptomatiques chez les patients CRS avec des polypes nasaux.
3. Points financiers du deuxième trimestre 2024 : 67,5 millions de dollars en liquidités et équivalents, 13,3 millions de dollars en dépenses de R&D, et 5,1 millions de dollars en frais généraux et administratifs.
4. La perte nette pour le deuxième trimestre 2024 était de 48,1 millions de dollars, contre 15,6 millions de dollars au deuxième trimestre 2023.
5. Des mesures de réduction des coûts ont été mises en œuvre, y compris une réduction de 75% de la main-d'œuvre et la suspension du développement de LYR-220.
Lyra Therapeutics (NASDAQ: LYRA) hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und ein Unternehmensupdate gegeben. Die wichtigsten Punkte sind:
1. Hauptfokus auf die Ergebnisse der ENLIGHTEN 1 Phase 3 Erweiterungsstudie, die im vierten Quartal 2024 erwartet werden, und auf die Ergebnisse der entscheidenden ENLIGHTEN 2 Phase 3 Studie, die im ersten Halbjahr 2025 erwartet werden.
2. Weitere Analysen der ENLIGHTEN 1-Daten zeigten, dass LYR-210 symptomatische Endpunkte bei CRS-Patienten mit Nasenpolypen verbesserte.
3. Finanzielle Höhepunkte für das zweite Quartal 2024: 67,5 Millionen Dollar in Bar und Äquivalenten, 13,3 Millionen Dollar an F&E-Ausgaben und 5,1 Millionen Dollar an allgemeinen Verwaltungskosten.
4. Der Nettoverlust für das zweite Quartal 2024 betrug 48,1 Millionen Dollar, im Vergleich zu 15,6 Millionen Dollar im zweiten Quartal 2023.
5. Kostenreduzierende Maßnahmen wurden umgesetzt, einschließlich einer Reduzierung des Personals um 75% und einer Unterbrechung der Entwicklung von LYR-220.
- LYR-210 showed improvement over control in symptomatic endpoints for CRS patients with nasal polyps
- Cash runway extended into Q1 2026
- ENLIGHTEN 2 trial enrollment on track, with results expected in 1H 2025
- Implemented cost-cutting measures to preserve capital
- LYR-210 did not meet primary endpoint in ENLIGHTEN 1 Phase 3 trial
- Net loss increased to $48.1 million in Q2 2024 from $15.6 million in Q2 2023
- 75% workforce reduction implemented
- Development of LYR-220 paused
- Impairment costs of $24.7 million incurred in Q2 2024
Insights
Lyra Therapeutics' Q2 2024 results paint a challenging picture. The company's cash position has significantly decreased from
The net loss for Q2 2024 ballooned to
While the company projects cash runway into Q1 2026, the burn rate is alarming. Investors should closely monitor upcoming trial results, as they will be important for Lyra's future prospects and potential need for additional financing.
The ENLIGHTEN 1 trial results for LYR-210 present a mixed bag. While the primary endpoint wasn't met in the overall CRS population, subgroup analysis revealed promising results in CRS patients with nasal polyps. The 3CS score improvement of 2.25 points (p=0.0058) in this subgroup is clinically meaningful.
Particularly intriguing is the effect in patients with moderate to severe nasal congestion, showing a 2.94-point improvement in 3CS score (p=0.0017). This suggests LYR-210 might be more effective in a specific patient population, potentially leading to a targeted approach in future trials or applications.
However, it's important to await the ENLIGHTEN 1 extension study results (Q4 2024) and ENLIGHTEN 2 pivotal trial results (1H 2025) for a comprehensive assessment. These upcoming data points will be critical in determining LYR-210's true potential and Lyra's path forward in the competitive CRS treatment landscape.
Lyra's strategic pivot following the ENLIGHTEN 1 setback is noteworthy. The 75% workforce reduction and pausing of LYR-220 development demonstrate a laser focus on the ongoing ENLIGHTEN program for LYR-210. This cost-cutting measure, while drastic, could extend the company's runway and allow it to see through the critical upcoming trial results.
The market for CRS treatments remains substantial, with an estimated 30 million patients in the US alone. If Lyra can successfully target the subgroup of CRS patients with nasal polyps, as suggested by the additional ENLIGHTEN 1 analysis, it could still capture a significant market share.
However, investor confidence has likely been shaken by the recent setbacks. The company's ability to rebuild trust will hinge on the forthcoming trial results and its capacity to articulate a clear, data-driven path forward. The next 6-12 months will be important for Lyra's market position and investor perception.
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned –
– In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps –
WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the second quarter ended June 30, 2024 and provided a corporate update.
“While we clearly recognize the disappointment of not meeting the primary endpoint in the previously-announced ENLIGHTEN 1 Phase 3 trial, our potential pathway to approval for LYR-210 in CRS without nasal polyps can only be determined once we unblind and analyze the full data set from the ENLIGHTEN pivotal program,” said Maria Palasis, Ph.D., President and CEO of Lyra Therapeutics. “Today we are disclosing that our further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps, which we believe reinforces the therapeutic potential of our product candidates.”
Dr. Palasis continued, “While we intend to remain opportunistic about strategic options, our primary focus remains on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210 in CRS patients with and without nasal polyps: the ENLIGHTEN 1 52-week extension study with results expected in Q4 2024 and the ENLIGHTEN 2 pivotal trial with enrollment on track and results expected in the first half of 2025. We plan to be pragmatic and data-driven as we determine our path forward for CRS patients, investors, and other stakeholders.”
Highlights from May 2024 ENLIGHTEN 1 Pivotal Results and Subsequent Cost-cutting Measures
- On May 6, Lyra announced topline results from the Phase 3 ENLIGHTEN 1 trial showing that LYR-210 did not meet its primary endpoint of statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. LYR-210 was generally well tolerated, with no product-related serious adverse events.
- Following the ENLIGHTEN 1 results disclosed in May, Lyra announced cost-cutting measures to preserve capital, including a reduction in force of approximately
75% of its workforce in addition to other measures to reduce costs and streamline operations. In connection with the reduction in force, which impacted 87 employees, Lyra stopped manufacturing and commercialization efforts and is seeking to sublease its three leaseholds to significantly reduce the Company’s operating costs. Furthermore, Lyra paused development efforts for LYR-220 in an effort to focus on the ongoing ENLIGHTEN Phase 3 program evaluating LYR-210.
Additional Analysis from ENLIGHTEN 1 for CRS Patient Subgroup with Nasal Polyps
- Further analysis of the ENLIGHTEN 1 data shows that LYR-210 demonstrated a positive effect compared to sham control in 3CS and nasal congestion scores at 24 weeks in the CRS patient subgroup with nasal polyps.
- Treatment with LYR-210 resulted in a mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2.25 points (p-value 0.0058) in the CRS patient subgroup with nasal polyps. This improvement was demonstrated despite the inclusion of only grade 1 nasal polyps in the study and without a threshold for nasal congestion score.
- For patients with nasal congestion score equal to or greater than 2 (that is moderate to severe symptom) at baseline in the CRS patient subgroup with nasal polyps, treatment with LYR-210 resulted in a mean (SE) improvement in the 3CS score of 3.69 (0.470) points, compared to 0.75 (0.685) points in sham control for a difference of 2.94 points (p-value 0.0017).
- Treatment with LYR-210 resulted in a mean (SE) improvement in the nasal congestion score of 1.20 (0.159) points, compared to 0.42 (0.243) points in sham control for a difference of 0.73 points (p-value 0.0216) in the CRS patient subgroup with nasal polyps and nasal congestion score equal to or greater than 2 at baseline.
Milestones for Ongoing ENLIGHTEN Pivotal Program of LYR-210 in CRS
- Enrollment in ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing; enrollment completion is expected in the second half of 2024.
- Topline results from ENLIGHTEN 2 are expected in the first half of 2025.
- Results from the ENLIGHTEN 1 52-week extension study are expected in Q4 2024.
Second Quarter 2024 Financial Highlights
Cash, cash equivalents and short-term investments as of June 30, 2024 were
Research and development expenses for the quarter ended June 30, 2024 were
The increase in research and development expenses for the three months ended June 30, 2024 was primarily attributable to an increase of
General and administrative expenses for the quarter ended June 30, 2024 were
The increase in general and administrative expenses for the three months ended June 30, 2024 was primarily driven by an increase of
The Company incurred impairment costs related to property and equipment of
The Company incurred impairment costs related to our right-of-use asset of
The Company incurred a restructuring charge in the amount of
Net loss for the second quarter 2024 was
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS). Lyra Therapeutics has two product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioabsorbable nasal implants designed to be administered in a simple, in-office procedure and are intended to deliver six months of continuous anti-inflammatory drug therapy (7500µg mometasone furoate) to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase 3 clinical program, has a smaller dimension and is intended for patients with standard anatomy, primarily patients who have not undergone ethmoid sinus surgery. LYR-220 is a larger implant designed for CRS patients whose nasal cavity is enlarged due to previous ethmoid sinus surgery. These two product candidates are designed to treat the estimated four million CRS patients in the United States who fail medical management each year. For more information, please visit www.lyratx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, our ongoing ENLIGHTEN 1 extension study and expectation for data in Q4 2024, our ongoing ENLIGHTEN 2 trial and our expectation for data in 1H 2025, our cash runway into 2026 and plans to update investors regarding our cash runway, and our plans to evaluate potential strategic options to maximize shareholder value. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: any potential financial or strategic option we pursue in order to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all; our ability to sublease or assign our three leaseholds, which represent significant operating costs; our incurrence of significant losses since inception and expectation to incur significant additional losses for the foreseeable future; our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern; our need for significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved; the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for the Company to raise capital; we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts; following the failure of our ENLIGHTEN 1 Phase 3 trial evaluating LYR-210 for the treatment of CRS to meet its primary endpoint, which was announced in May 2024, there is significant uncertainty about the Company’s ability to complete development of LYR-210 and our ability to obtain regulatory approval for LYR-210 is at least significantly delayed and may not be possible; our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaq’s continued listing requirements; our loss of key personnel significantly and adversely affects our ability to manufacture our product candidates, among other activities; we are no longer engaged in the manufacturing of our product candidates in-house; our business is highly dependent on the success of our most advanced product candidate, LYR-210; clinical trials required for our current product candidate and any future product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired; any failure by a third party to conduct our pre-clinical or clinical trials according to good clinical practices and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates; even if LYR-210 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success; if our collaborations are not successful, including with LianBio our product candidates may not reach their full market potential; our ability to manage our obligations under our license and other strategic agreements may divert management time and our limited resources, causing delays or disruptions to our business; our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities; failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions; developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets; the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue; if we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our market; the impact of international terrorism, political unrest and wars on our business; and the impact of other events such as the COVID-19 pandemic may adversely impact our business and operations, including our clinical trials. These and other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
LYRA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share data) | ||||||||
June 30, | December 31, | |||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 31,905 | $ | 22,353 | ||||
Short-term investments | 35,593 | 80,400 | ||||||
Prepaid expenses and other current assets | 1,937 | 2,068 | ||||||
Total current assets | 69,435 | 104,821 | ||||||
Property and equipment, net | 1,665 | 2,043 | ||||||
Operating lease right-of-use assets | 21,490 | 33,233 | ||||||
Restricted cash | 1,992 | 1,392 | ||||||
Other assets | — | 1,111 | ||||||
Total assets | $ | 94,582 | $ | 142,600 | ||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 4,971 | $ | 3,131 | ||||
Restructuring liability | 3,127 | — | ||||||
Accrued expenses and other current liabilities | 6,095 | 9,374 | ||||||
Operating lease liabilities | 4,269 | 5,434 | ||||||
Deferred revenue | 814 | 1,658 | ||||||
Total current liabilities | 19,276 | 19,597 | ||||||
Operating lease liabilities, net of current portion | 32,479 | 21,447 | ||||||
Deferred revenue, net of current portion | 11,850 | 12,136 | ||||||
Total liabilities | 63,605 | 53,180 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Preferred stock, and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — | ||||||
Common stock, June 30, 2024 and December 31, 2023; 65,455,735 and 57,214,550 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 65 | 57 | ||||||
Additional paid-in capital | 412,854 | 400,685 | ||||||
Accumulated other comprehensive income (loss), net of tax | (4 | ) | 33 | |||||
Accumulated deficit | (381,938 | ) | (311,355 | ) | ||||
Total stockholders’ equity | 30,977 | 89,420 | ||||||
Total liabilities and stockholders’ equity | $ | 94,582 | $ | 142,600 |
LYRA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (in thousands, except share and per share data) | |||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||
Collaboration revenue | $ | 598 | $ | 458 | $ | 1,130 | $ | 868 | |||||||||
Operating expenses: | |||||||||||||||||
Research and development | 13,264 | 10,799 | 31,502 | 23,395 | |||||||||||||
General and administrative | 5,139 | 4,570 | 10,957 | 9,697 | |||||||||||||
Impairment of property and equipment | 1,883 | 1,592 | 1,883 | 1,592 | |||||||||||||
Impairment of right-of-use asset | 22,836 | — | 22,836 | — | |||||||||||||
Restructuring and other related charges | 6,450 | — | 6,450 | — | |||||||||||||
Total operating expenses | 49,572 | 16,961 | 73,628 | 34,684 | |||||||||||||
Loss from operations | (48,974 | ) | (16,503 | ) | (72,498 | ) | (33,816 | ) | |||||||||
Other income: | |||||||||||||||||
Interest income | 855 | 897 | 1,941 | 1,969 | |||||||||||||
Total other income | 855 | 897 | 1,941 | 1,969 | |||||||||||||
Loss before income tax expense | (48,119 | ) | (15,606 | ) | (70,557 | ) | (31,847 | ) | |||||||||
Income tax expense | (12 | ) | (12 | ) | (26 | ) | (26 | ) | |||||||||
Net loss | (48,131 | ) | (15,618 | ) | (70,583 | ) | (31,873 | ) | |||||||||
Other comprehensive loss: | |||||||||||||||||
Unrealized holding loss on short-term investments, net of tax | (29 | ) | (15 | ) | (37 | ) | (37 | ) | |||||||||
Comprehensive loss | $ | (48,160 | ) | $ | (15,633 | ) | $ | (70,620 | ) | $ | (31,910 | ) | |||||
Net loss per share attributable to common stockholders— basic and diluted | $ | (0.74 | ) | $ | (0.36 | ) | $ | (1.09 | ) | $ | (0.79 | ) | |||||
Weighted-average common shares outstanding— basic and diluted | 65,459,678 | 43,676,387 | 64,739,520 | 40,273,472 |
FAQ
What were Lyra Therapeutics' Q2 2024 financial results?
When are the results for ENLIGHTEN 1 extension study and ENLIGHTEN 2 trial expected for LYRA?
What cost-cutting measures did Lyra Therapeutics (LYRA) implement in 2024?